Alprolix

DRUG3 trials

Sponsors

Swedish Orphan Biovitrum

Conditions

Haemophilia AHaemophilia BHemophilia B

Unknown Phase

A Study to Evaluate the Real-world Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

CompletedNCT03055611

Swedish Orphan BiovitrumHaemophilia A, Haemophilia B

Start: 2017-05-09End: 2022-04-19Updated: 2024-10-02

A Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B in France

CompletedNCT03655340

Swedish Orphan BiovitrumHaemophilia B

Start: 2018-09-12End: 2022-03-16Updated: 2024-09-19

An International Study to Evaluate the Real-world Effectiveness and Usage of Alprolix in Patients With Haemophilia B

CompletedNCT03901755

Swedish Orphan BiovitrumHemophilia B

Start: 2019-09-12End: 2024-03-12Updated: 2025-09-29

Related Papers

Post-Hoc Analyses of A-SURE and PREVENT Confirm the Effectiveness of rFVIIIFc Prophylaxis Across All Ages, BMIs, Severities and Inhibitor Histories

TH Open2026-06-16

Real-world usage and effectiveness of recombinant factor IX Fc in haemophilia B from the B-SURE study in France

Therapeutic Advances in Hematology2025-01-261 citations

Real-world usage and effectiveness of recombinant factor VIII/factor IX Fc in hemophilia A/B: final data from the 24-month, prospective, noninterventional PREVENT study in Germany.

2024-06-213 citations

Baseline Data from a 24-month Prospective, Non-interventional, Multicentre Study in Germany to Evaluate the Real-world Usage and Effectiveness of rFVIIIFc and rFIXFc in Patients with Haemophilia A or B (PREVENT)

Hämostaseologie2019-02-01